Tag Archives: ECL

Top 10 Casino Stocks To Watch Right Now

What happened

Mortgage real estate investment trust CYS Investments (NYSE:CYS) announced today that it had agreed to be acquired by fellow mortgage REIT Two Harbors Investment (NYSE:TWO).

Generally speaking, when an acquisition is announced, the acquisition target’s stock rises and the acquirer’s stock drops, and that’s exactly what we’re seeing here. As of 3 p.m. EDT on Thursday, CYS Investments is up by more than 10%, while Two Harbors is down by about 3%.

Image Source: Getty Images.

So what

The reason for the pop in CYS Investments’ stock price is due to the terms of the merger agreement.

Specifically, Two Harbors is acquiring CYS in a cash and stock deal. However, CYS shareholders will receive a total of just $15 million, which translates to less than $0.10 per share, so the majority of this deal is stock-based.

Top 10 Casino Stocks To Watch Right Now: ProShares UltraShort Nasdaq Biotechnology(BIS)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each days returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund. Advisors’ Opinion:

  • [By Shane Hupp]

    News articles about ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProShares UltraShort Nasdaq Biotechnology earned a news impact score of 0.15 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.2593843139852 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

  • [By Shane Hupp]

    Bismuth (BIS) uses the hashing algorithm. Its genesis date was May 1st, 2017. Bismuth’s total supply is 11,579,876 coins and its circulating supply is 11,011,069 coins. The Reddit community for Bismuth is /r/cryptobismuth and the currency’s Github account can be viewed here. The official message board for Bismuth is bismuth.cz/forum. Bismuth’s official Twitter account is @cryptobismuth and its Facebook page is accessible here. The official website for Bismuth is bismuth.cz.

  • [By Shane Hupp]

    Bismuth (CURRENCY:BIS) traded 8.1% lower against the US dollar during the 24-hour period ending at 21:00 PM ET on June 17th. Bismuth has a total market cap of $14.34 million and $48,199.00 worth of Bismuth was traded on exchanges in the last day. One Bismuth coin can now be purchased for $1.35 or 0.00020851 BTC on major exchanges including Cryptopia and Octaex. During the last week, Bismuth has traded down 8.5% against the US dollar.

Top 10 Casino Stocks To Watch Right Now: Applied Industrial Technologies, Inc.(AIT)

In this annual report on Form 10-K, “Applied” refers to Applied Industrial Technologies, Inc., an Ohio corporation. References to “we,” “us,” “our,” and “the Company” refer to Applied and its subsidiaries. We are a leading industrial distributor in North America, Australia, and New Zealand, serving MRO (maintenance, repair, and operations) and OEM (original equipment manufacturing) customers in virtually every industry. In addition, the Company provides engineering, design, and systems integration for industrial and fluid power applications, as well as customized mechanical, fabricated rubber, and fluid power shop services. We add value for our customers by providing product-related technical application support and solutions to help customers minimize their production downtime, improve machine performance, and reduce overall procurement and maintenance costs. Applied and its predecessor companies have engaged in this business since 1923.   Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Applied Industrial Technologies (AIT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    AICHAIN (CURRENCY:AIT) traded down 1.9% against the U.S. dollar during the twenty-four hour period ending at 15:00 PM Eastern on February 16th. One AICHAIN token can now be purchased for $0.0008 or 0.00000021 BTC on major cryptocurrency exchanges including Allcoin, OTCBTC, BigONE and DEx.top. AICHAIN has a total market capitalization of $410,230.00 and $21,335.00 worth of AICHAIN was traded on exchanges in the last 24 hours. During the last seven days, AICHAIN has traded down 0.7% against the U.S. dollar.

Top 10 Casino Stocks To Watch Right Now: SteadyMed Ltd.(STDY)

SteadyMed Ltd. (referred to as “we”, “the Company” or “SteadyMed” in this Annual Report on Form 10-K) is a specialty pharmaceutical company focused on the development and commercialization of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs. Our primary focus is to obtain approval for the sale of Trevyent庐 for the treatment of pulmonary arterial hypertension, or PAH. We are also developing two drug product candidates for the treatment of post-surgical and acute pain in the home setting. Our drug product candidates are enabled by our proprietary PatchPump庐, which is a discreet, pre-filled, water-resistant and disposable parenteral drug administration technology. Our PatchPump technology is aseptically pre-filled with sterile liquid drug at the site of manufacture and pre-programmed to deliver an accurate, steady flow of drug to a patient, either subcutaneously or intravenously.   Advisors’ Opinion:

  • [By Stephan Byrd]

    Steadymed Ltd (NASDAQ:STDY) CEO Jonathan Rigby sold 88,831 shares of the company’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $4.66, for a total transaction of $413,952.46. Following the completion of the sale, the chief executive officer now owns 41,605 shares of the company’s stock, valued at $193,879.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Top 10 Casino Stocks To Watch Right Now: Ecolab Inc.(ECL)

Ecolab was incorporated as a Delaware corporation in 1924. Our fiscal year is the calendar year ending December 31.

In 2015, we took several actions to continue to invest in and build our business, including: the June 2015 acquisition of Jianghai Environmental Protection Co. Ltd, an industrial water treatment company headquartered in Changzhou, China; the November 2015 acquisition of the U.S. operations of Charlotte, N.C. – based Swisher Hygiene Inc, a provider of hygiene and sanitizing solutions for the foodservice, hospitality, retail and healthcare markets; and the November 2015 acquisition of the assets and operations of Calgary – based Ultra Fab Industries Ltd, which manufactures customized solutions and specialized chemical injection systems for the oil and gas industry. See Part II, Item 8, Note 4 of this Form 10-K for additional information about these three acquisitions as well as additional actions taken by the Company.   Advisors’ Opinion:

  • [By Ethan Ryder]

    TRADEMARK VIOLATION WARNING: “Ecolab (ECL) Sets New 52-Week High at $173.40” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at www.tickerreport.com/banking-finance/4218879/ecolab-ecl-sets-new-52-week-high-at-173-40.html.

  • [By Maxx Chatsko]

    Last year,Ecolab (NYSE:ECL) had to navigate headwinds including global currency fluctuations made worse by a strong U.S. dollar, rising delivery costs, and volatility in energy markets. The business attempted to offset cost increases by improving operating efficiency and increasing selling prices, but those efforts weren’t enough to stop fourth-quarter operating income from sliding 4% compared to 2017. Revenue increased 3% year over year.

  • [By Motley Fool Transcription]

    Ecolab Inc. (NYSE:ECL)Q4 2018 Earnings Conference CallFebruary 19, 2019, 1:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Garrett Baldwin]

    If the answer is no, then understand that you are not alone – and you need to click here now…

    Stocks to Watch Today: HSBC, NAVI, LUV
    Shares of HSBC Holdings Plc. (NYSE: HSBC) fell more than 2% in pre-market hours. The slide came after the bank announced that it anticipated “a weaker global economic outlook.” The bank also issued a warning about the upcoming Brexit and said that many of its customers in the United Kingdom are “understandably cautious about the immediate future.” The firm also issued a weaker earnings report than expected. The company to watch today is Navient Corp.(NASDAQ: NAVI), which is the largest student loan servicer in the country. Sallie Mae spun off the company in 2013. It has 12 million customers and services about $300 billion in loans. While no one likes student loans, a few key metrics show this stock is a raging buy right now. Here’s what you need to know to get your trading week started. Southwest Airlines Co. (NYSE: LUV) is under scrutiny from the Federal Aviation Administration. According to reports, a probe is underway on whether the company has failed to calculate checked baggage loads on flights correctly. The Wall Street Journal reports that several planes carried 1,000 pounds of cargo more than what was listed on flight paperwork. Look for earnings reports from Advance Auto Parts Inc.(NYSE: AAP), Ecolab Inc. (NYSE: ECL), La-Z-Boy Inc.(NYSE: LZB), LendingClub Corp. (NYSE: LC), and Texas Roadhouse Inc.(NASDAQ: TXRH).

    Follow Money MorningonFacebook, Twitter, and LinkedIn.

Top 10 Casino Stocks To Watch Right Now: TrovaGene, Inc.(TROV)

We are a molecular diagnostic company that focuses on the development and commercialization of a proprietary molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Our primary internal focus is to leverage our novel cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while our external focus includes entering into license agreements or collaborations to develop our technology in areas such as infectious disease, transplant medicine and prenatal genetics. We are leveraging our proprietary molecular diagnostic technology for the detection of cell-free DNA originating from diseased cell death that can be isolated and detected from urine, blood, and tissue samples to improve disease management.   Advisors’ Opinion:

  • [By Stephan Byrd]

    TrovaGene Inc (NASDAQ:TROV) shares saw strong trading volume on Thursday . 1,477,200 shares were traded during trading, an increase of 185% from the previous session’s volume of 517,912 shares.The stock last traded at $0.83 and had previously closed at $0.81.

  • [By Logan Wallace]

    Media stories about TrovaGene (NASDAQ:TROV) have trended somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TrovaGene earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 45.974011377318 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Top 10 Casino Stocks To Watch Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

KRN23 (UX023)

KRN23 is a fully human monoclonal antibody administered via subcutaneous injection that is designed to bind and reduce the biological activity of fibroblast growth factor 23 (FGF23), to increase abnormally low phosphate levels in patients with X-linked hypophosphatemia (XLH). Patients with XLH have low serum phosphate levels due to excessive phosphate loss into the urine, which is directly caused by the effect on kidney function of excess FGF23 production in bone cells. The Company is also developing KRN23 for the treatment of tumor-induced osteomalacia (TIO). TIO results from typically benign tumors that produce excess levels of FGF23, which can lead to severe hypophosphatemia, osteomalacia, bone fractures, fatigue, bone and muscle pain, and muscle weakness. The Company is conducting Phase II study.

rhGUS (UX003)

Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7), also known as Sly Syndrome. Patients with MPS 7 suffer from severe cellular and organ dysfunction that typically leads to death in the teens or early adulthood. MPS 7 is caused by a deficiency of the lysosomal enzyme beta-glucuronidase, which is required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). It has conducted preclinical studies to supp! ort the chronic IV administration of rhGUS.

UX007

The Company is developing UX007 for oral administration intended as a substrate replacement therapy for patients with long-chain fatty acid oxidation disorders (LC-FAOD). UX007 is a purified, pharmaceutical-grade form of triheptanoin, a specially designed synthetic triglyceride compound, created via a multi-step chemical process. UX007 is a medium odd-chain triglyceride of over seven-carbon fatty acids designed to provide substrate replacement for fatty acid metabolism and restore production of energy. Patients with LC-FAOD have a deficiency that impairs the ability to produce energy from fat, which can lead to depletion of glucose in the body, and severe liver, muscle, and heart disease, as well as death. The Company has initiated Phase III study in LC-FAOD. The Company is also developing UX007 for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS). Glut1 DS is caused by a mutation affecting the gene that codes for Glut1, which is a protein that transports glucose from the blood into the brain. UX007 is intended as a substrate replacement therapy to provide an alternative source of energy to the brain in Glut1 DS patients. The Company has initiated a Phase III study in Glut1 DS patients with the movement disorder phenotype.

Ace-ER (UX001)

The Company is developing aceneuramic acid extended-release (Ace-ER), formerly known as sialic acid extended-release (SA-ER), which is an extended-release, oral formulation of sialic acid for the treatment of GNE myopathy, which is also known as hereditary inclusion body myopathy (HIBM). GNE myopathy is characterized by severe progressive muscular myopathy, or disease in which muscle fibers do not function properly, with onset typically in the late teens or twenties. Patients with GNE myopathy have a genetic defect in the gene coding for a particular enzyme that is involved in the first step in the biosynthesis of sialic acid. Ace-ER is intended a! s a subst! rate replacement therapy designed to address sialic acid deficiency and restore muscle function in GNE myopathy patients. The Company has conducted a Phase II randomized, double-blind, placebo-controlled study of Ace-ER in 47 GNE myopathy patients.

rhPPCA (UX004)

Recombinant human protective protein cathepsin-A (rhPPCA), which it in-licensed from St. Jude Children’s Research Hospital, is in preclinical development as an enzyme replacement therapy for galactosialidosis, a rare lysosomal storage disease for which there are no approved drug therapies. Patients with galactosialidosis present with both soft tissue storage in the liver, spleen, and other tissues, as well as connective tissue (bone and cartilage) related disease. As with MPS 7, an enzyme deficiency results in accumulation of substrates in the lysosomes, causing skeletal and organ dysfunction, and death. It is continuing preclinical development of rhPPCA.

The Company competes with B. Braun Medical Inc.

Advisors’ Opinion:

  • [By Shane Hupp]

    BidaskClub downgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a hold rating in a report released on Wednesday morning.

  • [By Motley Fool Transcribers]

    Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)Q42018 Earnings Conference CallFeb. 19, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Casino Stocks To Watch Right Now: SPDR Wells Fargo Preferred Stock ETF (PSK)

SPDR Wells Fargo Preferred Stock ETF (the Fund) seeks to replicate the total return of the Wells Fargo Hybrid and Preferred Securities Aggregate Index (the Index). The Index is a modified market capitalization weighted index designed to measure the performance of non-convertible preferred stock and securities that are functionally equivalent to preferred stock, including, but not limited to, depositary preferred securities, perpetual subordinated debt and certain securities issued by banks and other financial institutions that are eligible for capital treatment with respect to such instruments akin to that received for issuance of straight preferred stock. In addition, the Fund may invest in securities that are not included in the Index, futures, options, swap contracts and other derivatives, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Fund’s investment advisor is SSgA Funds Management, Inc.
Advisors’ Opinion:

  • [By Shane Hupp]

    The firm also recently declared a monthly dividend, which was paid on Thursday, February 7th. Shareholders of record on Monday, February 4th were given a $0.20 dividend. This represents a $2.40 annualized dividend and a yield of 5.76%. The ex-dividend date was Friday, February 1st.

    TRADEMARK VIOLATION NOTICE: “SPDR Wells Fargo Preferred Stock ETF (PSK) Shares Sold by Regal Investment Advisors LLC” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at www.tickerreport.com/banking-finance/4139767/spdr-wells-fargo-preferred-stock-etf-psk-shares-sold-by-regal-investment-advisors-llc.html.

    About SPDR Wells Fargo Preferred Stock ETF

  • [By Max Byerly]

    SPDR Wells Fargo Preferred Stock ETF (NYSEARCA:PSK) announced a monthly dividend on Monday, September 3rd, Wall Street Journal reports. Investors of record on Wednesday, September 5th will be given a dividend of 0.20 per share on Monday, September 10th. This represents a $2.40 annualized dividend and a dividend yield of 5.51%. The ex-dividend date of this dividend is Tuesday, September 4th.

Top 10 Casino Stocks To Watch Right Now: Kopin Corporation(KOPN)

Kopin Corporation invents, develops, manufactures, and sells wearable technologies and display products in the United States, the Asia-Pacific, and Europe. The company offers Kopin Wearable technology that includes component technologies, which can be integrated to create products and proprietary headset systems, which use voice as the primary user interface and through the use of wireless technologies can contact other users, devices, or information from the cloud. It also provides principal display products, a miniature high density color or monochrome active matrix liquid crystal displays; CyberDisplay products, a single crystal silicon used in conventional integrated circuits; optical lenses and backlights; and whisper chip to enhance the performance of existing audio systems and speech recognition engines. The companys display products are used in military, consumer, electronic, and industrial products, such as thermal weapon sights, digital cameras, virtual and augmented reality gaming, training and simulation products, and metrology tools. It sells its components directly and through distributors to original equipment manufacturers; and military display products directly to prime contractors of the United States government or to foreign companies. Kopin Corporation was founded in 1984 and is headquartered Westborough, Massachusetts.

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    But with dozens of publicly traded semiconductor stocks available to investors – ranging from large-cap giants like Intel Corp. (NASDAQ: INTC) to micro-cap vendors like Kopin Corp. (NASDAQ: KOPN) – it is difficult to know which ones are poised to break out.

  • [By Logan Wallace]

    Kopin (NASDAQ:KOPN) and Pixelworks (NASDAQ:PXLW) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Top 10 Casino Stocks To Watch Right Now: Rubicon Minerals Corp(RBY)

Rubicon Minerals Corporation, a mineral exploration company, engages in the acquisition, exploration, and development of mineral properties in Canada and the United States. It primarily explores for gold and base metal deposits. The company?s key asset is the Phoenix Gold Project located in the Red Lake gold camp, in the Province of Ontario. As of March 31, 2010, it controlled approximately 65,000 acres of prime exploration ground in the prolific Red Lake gold district of Ontario, Canada, as well as approximately 380,000 acres surrounding the Pogo Mine in Alaska and approximately 225,000 acres in northeast Nevada. The company was founded in 1996 and is headquartered in Vancouver, Canada.

Advisors’ Opinion:

  • [By Max Byerly]

    Rubycoin (RBY) is a proof-of-stake (PoS) coin that uses the Proof of Stake hashing algorithm. It was first traded on February 24th, 2014. Rubycoin’s total supply is 26,059,506 coins. The official website for Rubycoin is www.rubycoin.org. Rubycoin’s official Twitter account is @rubycoinorg. The Reddit community for Rubycoin is /r/rubycoin and the currency’s Github account can be viewed here.

  • [By Logan Wallace]

    Rubycoin (CURRENCY:RBY) traded 11.2% lower against the dollar during the twenty-four hour period ending at 7:00 AM ET on August 3rd. Rubycoin has a market cap of $8.39 million and $2,572.00 worth of Rubycoin was traded on exchanges in the last 24 hours. One Rubycoin coin can currently be bought for approximately $0.32 or 0.00004411 BTC on major cryptocurrency exchanges including Cryptopia, Bittrex and YoBit. During the last week, Rubycoin has traded 0.8% lower against the dollar.

Top 10 Casino Stocks To Watch Right Now: CareDx, Inc.(CDNA)

CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The companys commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Advisors’ Opinion:

  • [By Cory Renauer]

    Shares of CareDx (NASDAQ:CDNA),a specialized diagnostics company, jumped 16% during morningtrading in response to the company’s fourth-quarter earnings report. Investors pleased to see continued profitability have driven the stock 9.7% higher as of 3:29 p.m. EST on Thursday.

  • [By Motley Fool Transcribers]

    CareDx Inc (NASDAQ:CDNA)Q42018 Earnings Conference CallMarch 06, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Craig Hallum set a $35.00 target price on CareDx (NASDAQ:CDNA) in a research report sent to investors on Wednesday morning, The Fly reports. The firm currently has a buy rating on the stock.

  • [By Shane Hupp]

    Shares of CareDx Inc (NASDAQ:CDNA) were up 6.3% during mid-day trading on Wednesday . The company traded as high as $27.48 and last traded at $27.34. Approximately 568,546 shares traded hands during trading, an increase of 8% from the average daily volume of 525,423 shares. The stock had previously closed at $25.73.